MedPath

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)

Phase 3
Completed
Conditions
Bipolar Depression
Interventions
Drug: Placebo + (lithium or divalproex)
Registration Number
NCT00868452
Lead Sponsor
Sumitomo Pharma America, Inc.
Brief Summary

This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe when added to treatment with lithium or Divalproex for the treatment of patients with bipolar I depression.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
348
Inclusion Criteria
  • Subject is diagnosed with bipolar I disorder, most resent episode depressed
  • Subject must have a lifetime history of at least one bipolar manic or mixed episode
  • Subject must be taking lithium or divalproex at least 28 days prior to screening
Exclusion Criteria
  • History of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
  • Subject has been hospitalized for a manic or mixed episode within 60 days prior to randomization
  • Imminent risk of suicide or injury to self, others, or property

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Lurasidonelurasidone + (lithium or divalproex)-
PlaceboPlacebo + (lithium or divalproex)-
Primary Outcome Measures
NameTimeMethod
Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)Baseline, Week 6

MADRS total score ranges from a minimum of 0 to a maximum of 60. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Secondary Outcome Measures
NameTimeMethod
Mean Change From Baseline to Endpoint (Week 6) in: Clinical Global Impression Bipolar Version, Severity of Illness (CGI-BP-S) Score (Depression)Baseline Week 6

CGI-EP-S depression score ranges from a minimum of 0 to a maximum of 7. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Mean Change From Baseline to Endpoint (Week 6) in: Sheehan Disability Scale (SDS) Total ScoreBaselin Week 6

STS total score ranges from a minimum of 0 to a maximum of 30. Lower values represent a better score, higher values represent a worse score. Similarly, greater negative change from baseline represents improvement, and positive changes from baseline represent worsening.

Trial Locations

Locations (71)

Clintrial, s.r.o.

🇨🇿

Praha, Czech Republic

Manobal Med. Research Centre

🇮🇳

Lucknow, Uttar Prad, India

Spitalul Clinic Judetean de Urgenta Cluj

🇷🇴

Cluj-Napoca, Romania

Bekhterev Scientific Research Psychoneurological Institute

🇷🇺

St. Petersburg, Russian Federation

Psychoneurology Dispensary #4

🇷🇺

St. Petersburg, Russian Federation

Spandana Nursing Home

🇮🇳

Bangalore, Karna, India

Sheth Vadilal Sarabhai General Hospital

🇮🇳

Ahmedabad, Gujarat, India

Spitalul Clinic de Psihaiatrie Prof. Dr. Alexandru Obregia

🇷🇴

Bucuresti, Romania

Spitalul Judetean de Urgenta Pitesti Sectia de Psihiatric

🇷🇴

Pitesti, Romania

Spitalul Clinic de Urgenta Militar Central "Prof. Dr. Carol" Psihiatrie

🇷🇴

Bucuresti, Romania

Spitalul Clinic de Neurologie si Psihiatrie Oradea

🇷🇴

Oradea, Romania

City Psychiatric Hospital #2 of St. Nikolay Chudotvorets

🇷🇺

St. Petersburg, Russian Federation

Moscow Medical Academy named I.M. Sechenov

🇷🇺

Moscow, Russian Federation

LLC International Medical Centre "SOGAZ"

🇷🇺

St. Petersburg, Russian Federation

Reg. Clinic Psych. Hosp., Dept 11, DNMU n.a.M. Gorkiy

🇺🇦

Donetsk, Ukraine

Cedars-Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Mood Disorders Program-UHCMC

🇺🇸

Cleveland, Ohio, United States

Midwest Research Group

🇺🇸

St. Charles, Missouri, United States

Woodland International Research Inc.

🇺🇸

Little Rock, Arkansas, United States

CNRI - San Diego, LLC

🇺🇸

San Diego, California, United States

Depression and Anxiety Disorders Research Institue

🇺🇸

Tampa, Florida, United States

J. Gary Booker, MD

🇺🇸

Shreveport, Louisiana, United States

Synergy Escondido

🇺🇸

Escondido, California, United States

Sheppard Pratt Health System,6501 North Charles Street

🇺🇸

Baltimore, Maryland, United States

Stanford University School of Medicine

🇺🇸

Stanford, California, United States

Capital Clinical Research,5515 Security Lane, Suite 525

🇺🇸

Rockville, Maryland, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

BIALBI s.r.o. Psychiatricke oddeleni

🇨🇿

Litomerice, Czech Republic

Richard H. Weisler , M.D., PA.,& Associates, 700 Spring Forest Road, Suite 125

🇺🇸

Raleigh, North Carolina, United States

University of California at Irvine Medical Center

🇺🇸

Orange, California, United States

Albuquerque Neuroscience Inc.,101 Hospital Loop, Suite 209

🇺🇸

Albuquerque, New Mexico, United States

Vijayawada Institute of Mental Health and Neurosciences, Psychiatry

🇮🇳

Vijaywada, Andh Prad, India

South Coast Clinical Trials, Inc.

🇺🇸

Anaheim, California, United States

Collaborative Neuroscience Network Inc.,12772 Valley View Street

🇺🇸

Garden Grove, California, United States

CNRI - Los Angeles LLC,8309 Telegraph Road

🇺🇸

Pico Rivera, California, United States

MetroHealth System

🇺🇸

Cleveland, Ohio, United States

Psychiatricka ambulance

🇨🇿

Brno - mesto, Czech Republic

Cosmos Hospitals-Delhi Psychiatry Center-Dept. of Psychiatry

🇮🇳

Delhi, India

Lake Charles Clinical Trials LLC,700 Spring Forest Road

🇺🇸

Raleigh, North Carolina, United States

Praktyka Lekarska Sensorium S.M.O.

🇵🇱

Skorzewo, Poland

FutureSearch Clinical Trials, LLC., 4200 Marathon Blvd., Suite 200

🇺🇸

Austin, Texas, United States

Jana Thomsen

🇩🇪

Berlin BE, Germany

SV Medical College

🇮🇳

Tirupati, Andh Prad, India

Midwest Clinical research Center, One Elizabeth Place, Suite G-3

🇺🇸

Dayton, Ohio, United States

Wojewodzki Szpital Brodnowski SP ZOZ

🇵🇱

Warszawa, Poland

Dey Clinic

🇿🇦

Pretoria, Gauteng, South Africa

Samvedna Hospitals

🇮🇳

Ahmedabad, Gujarat, India

CRI Worldwide, LLC

🇺🇸

Philadelphia, Pennsylvania, United States

Medical Services Prague s.r.o.

🇨🇿

Praha, Czech Republic

R.K. Yadav Memorial Mental Health & De-Addiction Hospital

🇮🇳

Jaipur, Rajasthan, India

Zans Ritter, Marcel

🇫🇷

Orvault, France

Paarl Medical Centre

🇿🇦

Paarl, W. Cape, South Africa

Vereeniging Medi-Clinic

🇿🇦

Vereeniging, Free State, South Africa

Sujata Birla Hospital & Research Centre

🇮🇳

Nashik, Mahara, India

Clinika

🇿🇦

Port Elizabeth, E. Cape, South Africa

Reg. Ci.Ps.H.n.a.O.F.Maltsev, Fem.Ac.Gen.Ps. D.5B,HESIU UM

🇺🇦

Poltava, Ukraine

Catalina Research Institute

🇺🇸

Chino, California, United States

American Medical Research, Inc., 1200 Harger Road Suite 415

🇺🇸

Oak Brook, Illinois, United States

University of Colorado

🇺🇸

Aurora, Colorado, United States

Hopital Caremeau, Service de Psychiatrie A

🇫🇷

Nimes Cedex, France

Psychiatricka ambulance Prosek

🇨🇿

Praha, Czech Republic

Shree Hatkesh Health Foundation

🇮🇳

Junagadh, Gujarat, India

Mental Illness Treatment Rehabilitation Foundation (MITR)

🇮🇳

Ahmedabad, Gujarat, India

ZOZ Poradnia Zdrowia Psychicznego

🇵🇱

Chelmno, Poland

Spitalul Clinic de Neuropsihiatrie Craiova

🇷🇴

Craiova, Romania

Russian State Medical University

🇷🇺

Moscow, Russian Federation

Cape Trial Centre

🇿🇦

Cape Town, W. Cape, South Africa

Odesa Regional Psychoneurological Dispensary

🇺🇦

Odesa, Ukraine

CRI"Cl. Psych.Hosp.#1, Fem Psych.Dept.#2, Male Psych.Dept.#1

🇺🇦

Simferopol, Ukraine

Reg. Psych. Hosp. n.a. O.Yuschenko, Dept. #21, VNMUn.a.M. Pirog

🇺🇦

Vinnitsia, Ukraine

American Medical Research Inc.,1200 Harger Road Suite 415

🇺🇸

Oak Brook, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath